Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 50/100

Failure Rate

14.3%

3 terminated/withdrawn out of 21 trials

Success Rate

82.4%

-4.1% vs industry average

Late-Stage Pipeline

24%

5 trials in Phase 3/4

Results Transparency

0%

0 of 14 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 2
10(52.6%)
Phase 3
4(21.1%)
N/A
4(21.1%)
Phase 4
1(5.3%)
19Total
Phase 2(10)
Phase 3(4)
N/A(4)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (21)

Showing 20 of 21 trials
NCT01805557Phase 2Completed

Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

Role: collaborator

NCT05019989Not ApplicableCompleted

Trial of Diet, Physical Activity and Breast Cancer Recurrences: the DIANA-5 Study

Role: collaborator

NCT01739608Not ApplicableCompleted

Participation and Detection Rate of Screening CT Colonography and Screening Sigmoidoscopy

Role: lead

NCT02618538Completed

The Andromeda Study.Predictive Value of Combined Criteria to Tailor Breast Cancer Screening.

Role: lead

NCT02590315Phase 4Unknown

Tomosynthesis Versus Digital Mammography in a Population-based Screening Program

Role: lead

NCT00916708Not ApplicableUnknown

Trial Between Two Follow up Regimens With Different Test Intensity in Endometrial Cancer Treated Patients

Role: collaborator

NCT01251627Phase 2Completed

Multicenter Study to Assess the Efficacy of Decitabine in the Treatment of Chronic Myelomonocytic Leukemia

Role: collaborator

NCT00784537Phase 2Completed

High-dose Chemotherapy and Stem Cell Transplantation, in Patients PET-2 Positive, After 2 Courses of ABVD and Comparison of RT Versus no RT in PET-2 Negative Patients

Role: collaborator

NCT03118882Not ApplicableCompleted

STI.VI. Study: How to Improve Lifestyles in Screening Contexts

Role: lead

NCT00786851Phase 2Completed

Salvage Treatment With Lenalidomide and Dexamethaosne (LEN-DEX) in Patients With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

Role: collaborator

NCT01523847Phase 2Completed

A Multi-centre Study of MBVD in Elderly and/or Cardiopathic Patients Affected by Hodgkin's Lymphoma (HL)

Role: collaborator

NCT01523860Phase 2Completed

Brief Chemoimmunotherapy With R+B+M Followed by R in Elderly Patients Advanced Stage Untreated Follicular Lymphoma

Role: collaborator

NCT00949741Completed

Observational Study for the Cytofluorimetric Analysis of Cerebrospinal Fluid in Non-Hodgkin's Lymphoma Patients

Role: collaborator

NCT00902525Phase 2Terminated

Zevalin Twice in Aggressive Non-Hodgkin Lymphoma

Role: collaborator

NCT00907348Phase 2Unknown

Prospective Multicenter Dose Finding Phase II Pilot Trial to Evaluate Efficacy and Safety of LR-CHOP21 for Elderly Patients With Untreated Diffuse Large B Cell Lymphoma

Role: collaborator

NCT00803530Phase 2Terminated

Study of Association of Arsenic Trioxide (ATO) and Ascorbic Acid in Myelodysplastic Syndromes

Role: collaborator

NCT00804050Phase 3Terminated

Multicentric Study Comparison Between Erythropoietin and Erythropoietin Associated to Differentiating Therapy With Acid 13-cis-retinoic and Dihydroxyvitamin D3 in Myelodysplastic Syndromes Without Excess of Blasts

Role: collaborator

NCT00499018Phase 3Unknown

Dose Dense Chemotherapy + Rituximab +/-Intensified High Dose Chemoimmunotherapy With Support of Peripheral Autologous Stem Cell in Diffuse Large B-Cell Lymphoma

Role: collaborator

NCT00509379Phase 2Completed

Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

Role: collaborator

NCT00551980Phase 3Completed

The Efficacy of a Cognitive and Physical Intervention to Reduce Head and Muscle Pain in a Working Community

Role: collaborator